RT Journal Article
SR Electronic
T1 Utilizing novel fluorothymidine PET imaging in a phase I study of veliparib on an intermittent and continuous schedule given in combination with carboplatin in metastatic breast cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.01.20.20018218
DO 10.1101/2020.01.20.20018218
A1 Wesolowski, Robert
A1 Stover, Daniel G.
A1 Lustberg, Maryam B.
A1 Shoben, Abigail
A1 Zhao, Meng
A1 Mrozek, Ewa
A1 Layman, Rachel M.
A1 Macrae, Erin
A1 Duan, Wenrui
A1 Zhang, Jun
A1 Hall, Nathan
A1 Wright, Chadwick L.
A1 Schregel, Katharina
A1 Gillespie, Susan
A1 Berger, Michael
A1 Camp, Andrea
A1 Chalmers, Jeffrey J.
A1 Balasubramanian, Priya
A1 Miller, Brandon L.
A1 Amaya, Peter
A1 Andreopoulou, Eleni
A1 Sparano, Joseph
A1 Shapiro, Charles L.
A1 Villalona-Calero, Miguel Angel
A1 Geyer, Susan
A1 Chen, Alice
A1 Grever, Michael R.
A1 Knopp, Michael V
A1 Ramaswamy, Bhuvaneswari
YR 2020
UL http://medrxiv.org/content/early/2020/01/24/2020.01.20.20018218.abstract
AB Poly(ADP-ribose) polymerase inhibitors are FDA-approved for treatment of BRCA mutated metastatic breast cancer (MBC). Prior studies demonstrated benefit of adding oral PARPi veliparib to carboplatin and paclitaxel in BRCA mutation positive patients with MBC. We sought to find the recommended phase II dose (RP2D) and schedule of veliparib in combination with carboplatin in patients with advanced breast cancer, either triple negative (TNBC) or hormone receptor (HR) positive, HER2-negative with defective functional Fanconi Anemia (FA) DNA-repair pathway. Patients received escalating doses of veliparib on a 7, 14, or 21-day schedule with carboplatin every 3 weeks. Patients underwent [18]fluoro-3’-deoxythymidine (18FLT) positron emission tomography (PET) imaging, assessed in a blinded fashion. Forty-four patients (39 TNBC, 5 HR-positive/HER2-negative with a defective FA pathway) received a median of 5 cycles (range 1-36). Observed DLTs were grade (G) 4 thrombocytopenia (N=4), G4 neutropenia (N=1) and G3 akathisia (N=1). Common grade 3-4 toxicities included thrombocytopenia, lymphopenia, neutropenia, anemia, and fatigue. Of 43 patients evaluable for response, 18.6% achieved partial response and 48.8% had stable disease. Median progression free survival was 18.3 weeks. RP2D of veliparib was established at 250 mg twice daily on days 1-21 along with carboplatin at AUC 5. Patients with partial response had significant drop in SUVmax of target lesions between baseline and early 18FLT-PET (day 7-21; ptrend=0.006). Continuous dosing of veliparib and every three week carboplatin demonstrated activity and acceptable toxicity. Decrease in SUVmax on 18FLT-PET scan during the first cycle of this therapy can identify patients likely to have a response.IMPLICATIONS FOR PRACTICE The BROCADE studies suggest that patients with BRCA mutation benefit from addition of PARP inhibitor veliparib to carboplatin plus paclitaxel. In this study, we demonstrate that a higher dose of veliparib is tolerable and active in combination with carboplatin alone. With growing interest in imaging-based early response assessment, we demonstrate that decrease in 18FLT-PET SUVmax in the first cycle of therapy is significantly associated with response. Collectively, this study provides clarity on dosing of veliparib with carboplatin in advanced breast cancer while providing additional data on the potential for novel PET imaging modalities in monitoring therapy response.Competing Interest StatementDrs. Wesolowski, Stover, and Ramaswamy had full access to all the data in the study and had final responsibility for the decision to submit for publication. BR has received research support from Pfizer and served on academic advisory boards with Eisai and Pfizer. RW has received research support from Acerta and Astra Zeneca and served on advisory boards for PUMA and Pfizer. MV has received research support from Merck to institution to perform investigator initiated clinical trial. The rest of the authors declare that there are no competing interests.Clinical TrialNCT01251874Funding StatementThe study is supported by U01 CA076576. RW is supported by Translational Grant K12 CA133250 in experimental therapeutics from the National Cancer Institute and Cancer Clinical Investigator Team Leadership Award P30CA016058-42S2. DGS is supported by Susan G. Komen Career Catalyst Research Award.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll clinical trial data will be deposited in accordance with CTEP, NCI, and NIH guidelines.